[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 56, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 65, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 77000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 51, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 1034857, "exercisedValue": 0, "unexercisedValue": 11006}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 46, "title": "Senior VP, CFO & Principal Accounting Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 726300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 45, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Thompson M.A., M.S., Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chief Development Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.22, "open": 6.32, "dayLow": 6.23, "dayHigh": 6.54, "regularMarketPreviousClose": 6.22, "regularMarketOpen": 6.32, "regularMarketDayLow": 6.23, "regularMarketDayHigh": 6.54, "beta": 1.337, "forwardPE": -4.738806, "volume": 518421, "regularMarketVolume": 518421, "averageVolume": 491985, "averageVolume10days": 598160, "averageDailyVolume10Day": 598160, "bidSize": 900, "askSize": 800, "marketCap": 392180448, "fiftyTwoWeekLow": 2.59, "fiftyTwoWeekHigh": 7.33, "fiftyDayAverage": 5.2364, "twoHundredDayAverage": 4.7633, "currency": "USD", "enterpriseValue": 233838752, "floatShares": 34146900, "sharesOutstanding": 61760700, "sharesShort": 2395405, "sharesShortPriorMonth": 2742730, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0388, "heldPercentInsiders": 0.0065200003, "heldPercentInstitutions": 0.92791003, "shortRatio": 5.77, "shortPercentOfFloat": 0.039, "impliedSharesOutstanding": 61760700, "bookValue": 2.594, "priceToBook": 2.4479568, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -68169000, "trailingEps": -1.44, "forwardEps": -1.34, "pegRatio": -0.35, "enterpriseToEbitda": -3.268, "52WeekChange": 1.1896551, "SandP52WeekChange": 0.3288405, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.35, "targetHighPrice": 40.0, "targetLowPrice": 15.0, "targetMeanPrice": 20.6, "targetMedianPrice": 16.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 192442000, "totalCashPerShare": 3.116, "ebitda": -71548000, "totalDebt": 34100000, "quickRatio": 15.678, "currentRatio": 16.363, "debtToEquity": 21.284, "returnOnAssets": -0.25148, "returnOnEquity": -0.46217, "freeCashflow": -43788248, "operatingCashflow": -66588000, "financialCurrency": "USD", "trailingPegRatio": null}]